Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Advaxis Inc (NASDAQ:ADXS)

13.60
Delayed Data
As of Sep 04
 +0.20 / +1.49%
Today’s Change
2.50
Today|||52-Week Range
30.13
+69.79%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$427.0M

Company Description

Advaxis, Inc. is a clinical-stage biotechnology company, which intends to develop immunotherapies for cancer and infectious diseases. The company's platform technology is designed to generate a comprehensive immune response by serving as its own adjuvant, directing antigen presentation, increasing tumor infiltrating killer T-cells, and decreasing Tregs/MDSCs in the tumor. Advaxis was founded on June 5, 1987 and is headquartered in Princeton, NJ.

Contact Information

Advaxis, Inc.
305 College Road East
Princeton New Jersey 08540
P:(609) 452-9813
Investor Relations:

Employees

Shareholders

Mutual fund holders--
Individual stakeholders--
Other institutional--

Top Executives

Daniel J. O'ConnorPresident, Chief Executive Officer & Director
Gregory T. MayesCOO, Secretary, EVP & Head-Investor Relations
Sara BonsteinChief Financial Officer & Senior Vice President
Robert PetitChief Scientific Officer & Executive VP
David J. MauroChief Medical Officer & Executive Vice President